Table 2.
Univariate analysis of survival in SCLC patients with bone metastases at initial diagnosis.
| Subgroup | Median Survival (months) | 2-year survival rate (%) | p Value |
|---|---|---|---|
| Gender | |||
| Male | 10.4 | 7.2 | 0.226 |
| Female | 10.3 | 23.7 | |
| Age | |||
| <65 | 10.9 | 13.1 | 0.002 |
| ≥65 | 9.1 | 3.4 | |
| Smoke | |||
| Yes | 13.0 | 8.5 | 0.103 |
| No | 10.3 | 18.9 | |
| Coexisting extraosseous metastases | |||
| Yes | 8.0 | 2.1 | 0.000 |
| No | 12.2 | 17.7 | |
| Number of bone metastases | |||
| Single | 11.5 | 28.3 | 0.026 |
| Multiple | 9.3 | 5.3 | |
| Appendicular bone metastases | |||
| Yes | 9.3 | 10.6 | 0.992 |
| No | 10.5 | 9.7 | |
| Number of vertebra metastases | |||
| <3 | 10.9 | 14.5 | 0.01 |
| ≥3 | 8.67 | 2.9 | |
| T stage | |||
| T1/T2 | 10.0 | 8.9 | 0.231 |
| T3/T4 | 10.6 | 15.4 | |
| N stage | |||
| N0/N1/N2 | 66 | 15.8 | 0.009 |
| N3 | 36 | 0 | |
| LDH level | |||
| Normal | 11.5 | 16.0 | 0.048 |
| Elevated | 8.8 | 5.2 | |
| ALP | |||
| Normal | 10.4 | 10.1 | 0.832 |
| Elevated | 10.3 | 13.3 |
Abbreviations: LDH= lactate dehydrogenase; ALP= alkaline phosphatase